Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients
Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients
About this item
Full title
Author / Creator
on behalf of RESITRA , RESITRA , Len, Oscar , Gavaldà, Joan , María Aguado, José , Borrell, Núria , Cervera, Carlos , Miguel Cisneros, José , Cuervas‐Mons, Valentín , Gurguí, Mercè , Martin‐Dávila, Pilar , Montejo, Miguel , Muñoz, Patricia , Bou, Germán , Carratalà, Jordi , Torre‐Cisneros, Julián and Pahissa, Albert
Publisher
United States: The University of Chicago Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: The University of Chicago Press
Subjects
More information
Scope and Contents
Contents
Background. Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant (SOT) recipients, either by direct injury or in association with chronic allograft rejection or other opportunistic infections. Ganciclovir is the treatment of choice, but this agent requires intravenous administration, which affects its feasibility for long‐term...
Alternative Titles
Full title
Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_20858977
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_20858977
Other Identifiers
ISSN
1058-4838
E-ISSN
1537-6591
DOI
10.1086/523590
